N
YMAB

Nuveen’s Y-mAbs Therapeutics YMAB Stock Holding History

Nuveen’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-93,418
Closed -$421K – 3318
2025
Q2 		$421K Sell
93,418
-19,065
-17% -$85.7K ﹤0.01% 2935
2025
Q1 		$498K Hold
112,483
– – ﹤0.01% 2908
2024
Q4 		$881K Hold
112,483
– – ﹤0.01% 2764
2024
Q3 		$1.48M Hold
112,483
– – ﹤0.01% 2575
2024
Q2 		$1.36M Sell
112,483
-155,247
-58% -$2.1M ﹤0.01% 2570
2024
Q1 		$4.35M Sell
267,730
-132,210
-33% -$1.78M ﹤0.01% 2057
2023
Q4 		$2.73M Buy
399,940
+41,541
+12% +$240K ﹤0.01% 2270
2023
Q3 		$1.95M Sell
358,399
-66,432
-16% -$387K ﹤0.01% 2300
2023
Q2 		$2.88M Buy
424,831
+91,439
+27% +$685K ﹤0.01% 2180
2023
Q1 		$1.67M Buy
333,392
+229,329
+220% +$936K ﹤0.01% 2413
2022
Q4 		$508K Buy
104,063
+99
+0.1% +$719 ﹤0.01% 2879
2022
Q3 		$1.5M Sell
103,964
-4,062
-4% -$67.3K ﹤0.01% 2549
2022
Q2 		$1.63M Buy
108,026
+1,256
+1% +$14.7K ﹤0.01% 2541
2022
Q1 		$1.26M Buy
106,770
+1,261
+1% +$12.9K ﹤0.01% 2717
2021
Q4 		$1.62M Sell
105,509
-34,704
-25% -$742K ﹤0.01% 2665
2021
Q3 		$4M Sell
140,213
-21,412
-13% -$675K ﹤0.01% 2334
2021
Q2 		$5.46M Buy
161,625
+33,288
+26% +$1.07M ﹤0.01% 2195
2021
Q1 		$3.88M Buy
128,337
+1,967
+2% +$80.6K ﹤0.01% 2292
2020
Q4 		$6.26M Buy
126,370
+7,101
+6% +$328K ﹤0.01% 1953
2020
Q3 		$4.58M Sell
119,269
-32,461
-21% -$1.29M ﹤0.01% 1963
2020
Q2 		$6.55M Buy
151,730
+43,950
+41% +$1.66M ﹤0.01% 1748
2020
Q1 		$2.81M Buy
107,780
+2,271
+2% +$65.9K ﹤0.01% 2025
2019
Q4 		$3.3M Buy
105,509
+21,254
+25% +$629K ﹤0.01% 2209
2019
Q3 		$2.2M Buy
84,255
+4,357
+5% +$111K ﹤0.01% 2355
2019
Q2 		$1.83M Buy
+79,898
New +$1.83M ﹤0.01% 2476

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nuveen's YMAB Position: Q3 2025 in Review

Nuveen sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 93,418 shares — an estimated $421K sold.

Nuveen first reported a position in YMAB in Q2 2019 and held it in 25 quarters. The position peaked at $6.55M in Q2 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Nuveen reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nuveen sold 93,418 Y-mAbs Therapeutics shares in Q3 2025, an estimated $421K.
  • Nuveen first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 25 quarters.
  • Nuveen's Y-mAbs Therapeutics position peaked at $6.55M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.